STI-1386
AXP000135.1 · Oncolytic virus
- Platform
- HSV-1 (second-generation oncolytic, immune-payload armed)
- Originator
- Virttu Biologics / Sorrento Therapeutics
- Sponsor
- Sorrento Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| STI-1386 | preferred name, code | curator, ncit |
| Seprehvec | code | ncit |
| Oncolytic HSV-1 STI-1386 | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- second-generation oncolytic HSV-1 backbone; deletions not specified in NCIt
- Transgenes
- anti-PD-1 scFv-Fc, TGFBR2 decoy, IL12A, IL12B
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C187651
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Not yet recruiting | Phase 1 | 2023-08 | 2026-10 | 36 | Cancer; Cancer of Pancreas; Hepatic Metastasis; Sarcoma; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
Second-generation oncolytic HSV-1 expressing an anti-PD-1 scFv-Fc, a TGF-beta receptor II decoy and IL-12 (NCIt C187651); development name Seprehvec, after Sorrento/Virttu's first-generation Seprehvir (HSV1716, AXP000073). Phase 1b NCT05361954 was registered in 2022 but still shows 'not yet recruiting'; Sorrento filed for bankruptcy in 2023, so whether any patient was dosed is unverified.
How to cite
STI-1386 (AXP000135.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000135.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.